Trial Profile
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Pasireotide (Primary) ; Cabergoline
- Indications Acromegaly; Dumping syndrome; Pituitary ACTH hypersecretion
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals; Recordati
- 19 Jan 2024 This trial has been completed in France (Global end date: 25 July 2023).
- 23 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 18 Jun 2023 8-year interim results assessing long-term safety of pasireotide, presented at the 105th Annual Meeting of the Endocrine Society